Publications (150) Antonio Pineda Lucena publications

filter_list

2025

  1. Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML

    Molecular Therapy Oncology, Vol. 33, Núm. 1

  2. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma

    Journal of experimental & clinical cancer research : CR, Vol. 44, Núm. 1, pp. 13

  3. Towards a more inductive world for drug repurposing approaches

    Nature Machine Intelligence

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. An automated network-based tool to search for metabolic vulnerabilities in cancer

    Nature Communications , Vol. 15, Núm. 1

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  5. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

    Cell Death and Disease, Vol. 15, Núm. 11

  6. GeNNius: an ultrafast drug-target interaction inference method based on graph neural networks

    Bioinformatics (Oxford, England), Vol. 40, Núm. 1

  7. HDACi vorinostat protects muscle from degeneration after acute rotator cuff injury in mice

    Bone and Joint Research, Vol. 12, Núm. 4, pp. 169-183

  8. Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

    Cell Death Discovery, Vol. 10, Núm. 1

  9. Pharmacological inhibition of the integrated stress response accelerates disease progression in an amyotrophic lateral sclerosis mouse model

    British Journal of Pharmacology, Vol. 181, Núm. 3, pp. 495-508

  10. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

    Archivos de Bronconeumologia, Vol. 60, pp. S67-S76

  11. Study of pediatric invasive pneumococcal disease in the 13-pneumococcal conjugated vaccine era

    Diagnostic Microbiology and Infectious Disease, Vol. 110, Núm. 4

2023

  1. AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity

    Biomedicine and Pharmacotherapy, Vol. 169

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders

    Medical Microbiology and Immunology, Vol. 212, Núm. 1, pp. 93-102

  4. NMR-Based Mitochondria Metabolomic Profiling: A New Approach To Reveal Cancer-Associated Alterations

    Analytical Chemistry, Vol. 95, Núm. 45, pp. 16539-16548

  5. Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

    Biology, Vol. 12, Núm. 9

  6. Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses

    Frontiers in Cellular and Infection Microbiology, Vol. 13